The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. - Judge PK; Tuttle KR; Staplin N; Hauske SJ; Zhu D; Sardell R; Cronin L; Green JB; Agrawal N; Arimoto R; Mayne KJ; Sammons E; et al. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025)